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Abstract: New hetaryl- and alkylidenerhodanine derivatives 3a–d, 3e, and 4a–d were 
prepared from heterocyclic aldehydes 1a–d or acetaldehyde 1e. The treatment of several 
rhodanine derivatives 3a–d and 3e with piperidine or morpholine in THF under  
reflux, afforded (Z)-5-(hetarylmethylidene)-2-(piperidin-1-yl)thiazol-4(5H)-ones and  
2-morpholinothiazol-4(5H)-ones 5a–d, 6a–d, and (Z)-5-ethylidene-2-morpholinothiazol-
4(5H)-one (5e), respectively, in good yields. Structures of all compounds were determined 
by IR, 1D and 2D NMR and mass spectrometry. Several of these compounds were 
screened by the U.S. National Cancer Institute (NCI) to assess their antitumor activity 
against 60 different human tumor cell lines. Compound 3c showed high activity against 
HOP-92 (Non-Small Cell Lung Cancer), which was the most sensitive cell line, with  
GI50 = 0.62 μM and LC50 > 100 μM from the in vitro assays. In vitro antifungal activity of 
these compounds was also determined against 10 fungal strains. Compound 3e showed 
activity against all fungal strains tested, but showed high activity against Saccharomyces 
cerevisiae (MIC 3.9 μg/mL). 
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1. Introduction 
In recent years, the synthesis and pharmacological properties of several rhodanine derivatives have 
been reported [1,2]. Among them, the literature highlights the antibacterial activity of 5-arylidene 
rhodanine derivatives [3], antimicrobial activity of 5-hetarylidene rhodanine derivatives [4], and 
antifungal activity of 5-arylidene rhodanine-3-acetic acid [5] and 5-arylidene rhodanines [6]. The 
substitution of rhodanine derivatives at C-2 (C=S) of the ring has produced compounds with important 
biological activity [7]. This type of compounds has been used as precursors for the synthesis of new 
fused heterocyclic systems [8]. Recently, new hetarylmethylidene derivatives were synthesized by Xu 
and co-workers [9] from the reaction of 1,3-diarylpyrazole-4-carbaldehyde with rhodanine-3-acetic 
acid. These compounds showed important antimicrobial activity. Herein, we report the synthesis of 
some new hetarylmethylidene rhodanine derivatives and their antitumor and antifungal activities. 
2. Results and Discussion 
2.1. Chemistry 
New rhodanine derivatives were prepared from heterocyclic aldehydes 1a–d by different pathways, 
leading to the hetarylmethylidenerhodanine 3a–d and the rhodanine-3-acetic acid derivatives 4a–d. To 
obtain the expected compounds 3a–d, a mixture of rhodanine 2a with the respective heterocyclic 
aldehyde 1a–d and catalytic amounts of piperdine was heated for 4 h at reflux in absolute ethanol. In 
the case of 3a, a yellow solid was obtained which after spectroscopic characterization (IR, 1H and  
13C-NMR and mass spectrometry) was confirmed to be the proposed compound. It was obtained in 
86% yield (Scheme 1). 
Scheme 1. General methodology for the synthesis of rhodanine and rhodanine-3-acetic 
acid derivatives and their structures. 
 
Reagents and Conditions: i = (R' = H), piperidine (catalytic amounts), reflux, 4 h;  
ii = (R' = CH2COOH), MW (100 W, 100 °C, 30 psi), 5 min. 
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Compound 3a exhibited characteristic signals of its functional groups. The IR spectrum showed 
absorption bands at 3,134, 1,684 and 1,213 cm−1 associated with the –NH, C=O and C=S 
functionalities, respectively. In the 1H-NMR spectrum, a broad singlet at δ = 13.71 ppm was assigned 
to the –NH group and singlets at 7.39 and 2.40 ppm were assigned to the vinylidenic proton and to the 
methyl group of the pyrazole ring, respectively. The 13C-NMR spectrum showed signals at δ = 169.4 
and 195.5 ppm assigned to the (C=O) and (C=S) functionalities, respectively. All signals agree with 
the proposed structure 3a. Finally, the mass spectrum, showed a peak (m/z 301) corresponding to the 
molecular ion. Similar results were observed for compounds 3b–d, obtained in good yields, as shown 
in Table 1. 
Table 1. Melting points and yields for the hetarylmethylidene rhodanine derivatives 3a–d, 
3e and rhodanin-3-acetic acid derivatives 4a–d. 
Compound m.p. (°C) Yield (%) 
3a 294–295 86 
3b 307–309 91 
3c 315–317 86 
3d 230–231 85 
3e 145–147 64 
4a 279–281 81 
4b 254–256 53 
4c 263–265 92 
4d 232–234 63 
Chen and co-workers have previously reported the synthesis of rhodanine-3-acetic acid derivatives 
in acetic acid under reflux and using sodium acetate as catalyst [10]. Here we propose the use of 
microwave irradiation for the synthesis of these compounds with shorter reaction times and easier 
works-up. 
In this sense, a mixture of heterocyclic aldehyde 1a and rhodanine-3-acetic acid was subjected to 
microwave irradiation (CEM-focused microwave reactor) using DMF as solvent at 100 °C and 100 W 
of power for 5 min, leading to the formation of a yellow solid which was characterized by IR, 1H and 
13C-NMR and mass spectrometry to correspond to the desired compound 4a. It was obtained in 92% yield. 
In the 1H-NMR spectrum, we observed a broad singlet at 13.45 ppm assigned to the acid proton  
(–COOH) and a signal at 4.73 ppm assigned to methylene protons between the acid group and thiazole 
ring, while the remaining signals corresponded to rest of compound 4a. In the 13C-NMR spectrum, a 
signal at 167.2 ppm corresponding to a carbonyl carbon (–COOH) was observed. With the help of 
DEPT-135 at 45.0 ppm the signal assigned to the methylene carbon between the –COOH group and 
the rhodanine ring was discerned.  
The same procedure was followed to obtain compounds 4b–d in good yields (Scheme 1, Table 1), 
which highlights the efficiency of the microwave radiation for the synthesis of these compounds. The 
Z- configuration of compounds 3a–d and 4a–d was deduced based on the previously reported crystal 
structure of compounds of the (Z)-5-arylidenerhodanine type [11,12].  
Subsequently, compound 3a upon reflux during 18 h with an excess of piperidine (2 equiv.) in THF 
afforded a white solid accompanied by the loss of H2S, as detected by its characteristic smell (Scheme 2). 
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This solid corresponded to (Z)-5-(hetarylmethylidene)-2-(piperidin-1-yl)thiazol-4(5H)-one (5a, 85% 
yield), as confirmed by its IR, 1H, 13C-NMR and mass spectra. In the 1H-NMR spectrum of compound 
5a, a singlet at 8.1 ppm corresponding to the proton of the pyrazole ring, a singlet at 7.66 ppm 
corresponding to the vinylidenic proton, and two broad singlets (2H each one) at 4.03 and 3.60 ppm, 
assignable to the adjacent methylenes to nitrogen of the piperidine ring, were observed. 
Scheme 2. General methodology for the synthesis of (Z)-5-(hetarylmethylidene)-2-
(piperidin-1-yl)thiazol-4(5H)-ones and (Z)-5-(hetarylmethylidene)-2-morpholinothiazol-
4(5H)-ones and their structures. 
 
Reagents and Conditions: i = (R' = H), piperidine (2 equiv.), THF at reflux, 7–24 h. 
In the 13C-NMR spectrum, the disappearance of the characteristic signal of the (C=S) carbon atom, 
along with the appearance of aliphatic signals at 50.3, 49.6, 26.1, 25.4 and 24.0 ppm (corresponding to 
the piperidine moiety), confirmed the structure proposed for compound 5a. The mass spectrum showed 
a peak with (m/z 352) which is in accordance with the expected molecular ion for a structure like 5a. 
The same procedure was followed for hetarylmethylidenic derivatives 3b–d, with similar results, 
affording compounds 5b–d, as shown in Table 2. Based on these results; we decided to extend the 
same methodology to the hetarylmethylidenic derivatives 3a–d but using morpholine instead of 
piperidine. This approach led to the synthesis of the (Z)-5-(hetarylmethylidene)-2-morpholinothiazol 
4(5H)-ones 6a–d, Table 2. 
Table 2. Melting points and yields for the piperidine and morpholine derivatives 5a–d, 5e and 6a–d. 
Compound -X- m.p. (°C) Yield (%) 
5a -CH2- 141–143 85 
5b -CH2- 261–262 70 
5c -CH2- 262–264 95 
5d -CH2- 194–196 93 
5e -O- 193–195 45 
6a -O- 264–265 71 
6b -O- 270–272 62 
6c -O- 266–268 86 
6d -O- 206–208 85 
In a further experiment, the synthesis of the (Z)-5-ethylidene-2-thioxothiazolidin-4-one (3e) was 
achieved by refluxing during 7 h an ethanolic solution of rhodanine, paraldehyde and catalytic amounts 
of piperidine. A yellow solid was obtained in 64% yield. This compound was subjected to reaction 
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with morpholine as described above for compounds 6a–d, thereby obtaining a brown solid in 45% 
yield, which, by IR, 1H and 13C-NMR and MS methods was characterized as the compound 5e (Table 2). 
2.2. In Vitro Antifungal Activity 
Minimum Inhibitory Concentration (MIC) of compounds 3a–e, 4a–d, 5a–e and 6a–d were 
determined with the microbroth dilution methods M27-A3 and M38-A2 of CLSI [13,14] against a 
panel of 10 fungal species comprising four yeasts (Candida albicans, C. tropicalis, Cryptococcus 
neoformans and Saccharomyces cerevisiae), three Aspergillus spp. (A. niger, A. fumigatus and  
A. flavus) and three dermatophytes (Trichophyton rubrum, T. mentagrophytes and Microsporum gypseum]. 
Compounds with MICs > 250 μg/mL were considered inactive. MICs between 250–125 μg/mL were 
indicative of low activity; between 62.5–31.25 μg/mL, moderate activity; MICs  15.6 μg/mL, high 
activity. Among the last ones, compounds displaying MICs ≤ 10 μg/mL were considered of great 
interest for further development. In addition to MIC, active compounds (MICs  250 μg/mL) were 
tested for its capacity of killing fungi rather than inhibiting them through the determination of the 
Minimum Fungicidal Concentration (MFC). It was determined by plating an aliquote from each clear 
well of MIC determinations, onto a plate containing clear culture medium. After incubation, MFCs 
were determined as the lowest concentration of each compound showing no growth, which clearly 
indicated that fungi were dead rather than inhibited (the detailed methodology is explained in the 
Experimental section).  
Compounds 3a, 3b, 3d, 4b–d, 5a–e and 6a–d, were inactive (Table 3). In contrast, compounds 3c, 
3e and 4a showed varied activities, being 3e the one with the broadest and highest activity. An analysis 
of correlation between structure and activity showed that the most potent compound 3e possessed the 
simplest structure among the all tested compounds, possessing a thiazolidine ring and methyl 
substituent as the R moiety. The other structure with R = methyl (compound 5e) with a more complex 
structure containing a thiazole ring and morpholino substituent, did not possess activity up to 250 µg/mL. 
Table 3. In vitro antifungal activities (MIC and MFC values in μg/mL, showed as 
MIC/MFC) of hetarylidenerhodanine derivatives. 
Compound Structure 
Antifungal Activity  
MIC/MFC (μg/mL) 
Ca Ct Sc Cn Afu Afl Ani Mg Tr Tm 
3a 
 
>250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
3b 
 
>250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
3c 
 
>250 >250 >250 125/ 125 
250/ 
250 
250/ 
250 
250/ 
250 
125/ 
125 
125/ 
125 
125/ 
125 
3d 
 
>250 >250 >250 >250 >250 >250 >250 <250 <250 <250 
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Table 3. Cont. 
Compound Structure 
Antifungal Activity  
MIC/MFC (μg/mL) 
Ca Ct Sc Cn Afu Afl Ani Mg Tr Tm 
3e  
7.8/ 
31.2 
7.8/ 
31.2 
3.9/ 
15.6 
15.6/ 
62.5 
31.2/ 
250 
31.2/ 
250 
62.5/ 
250 
7.8/ 
7.8 
7.8/ 
15.6 
15.6/ 
15.6 
4a 
 
>250 >250 >250 >250 >250 >250 >250 125/  125 
62.5/ 
62.5 
62.5/ 
62.5 
4b 
 
>250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
4c 
 
>250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
4d 
 
>250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
5a 
 
>250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
5b 
 
>250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
5c 
 
>250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
5d 
 
>250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
5e >250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
6a 
 
>250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
6b 
 
>250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
6c 
 
>250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
6d 
 
>250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
amphotericin B - 0.78  0.50 0.25 0.50 0.50 0.50 0.12 0.07 0.07 
ketoconazole - 1.56  3.12 0.39 0.78 0.78 1.56 0.04 0.01 0.02 
terbinafine - 0.50  0.50 0.25 0.12 0.50 0.25 0.05 0.02 0.02 
Antifungal activity was determined with the microbroth dilution assay following the CLSI guidelines.  
Fungi used: C.a.: Candida albicans ATCC10231, C.t.: Candida tropicalis C131; C.n.: Cryptococcus 
neoformans ATCC32264, S.c.: Saccharomyces cerevisiae ATCC9763, A.n.: Aspergillus niger ATCC9029, 
A.fl.: Aspergillus flavus ATCC 9170, A.fu.: Aspergillus fumigatus ATCC 26934, M.g.: Microsporum gypseum 
C 115, T.r.: Trichophyton rubrum C113, T.m.: Trichophyton mentagrophytes ATCC 9972. 
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An analysis of the effect of the substituents other than the methyl group showed that those with  
4-methyl-1H-imidazol-5-yl [compounds named “b” (3, 4, 5 and 6)] or with 5-methylthiophen-2-yl 
[named “d” (3, 4, 5 and 6)] were inactive. On the other hand, among compounds with R = 1,3-
diphenyl-1H-pyrazol-4-yl (named “c”), or R = 1-methyl-3-phenyl-1H-pyrazol-4-yl (named “a”), 3c 
showed low broad spectrum of activity and 4a displayed moderate activity (MICs between  
62.5–125 μg/mL) respectively. Interestingly, the three active structures (3c, 3e and 4a) possess 
fungicidal rather than fungistatic activities, with MFC values between 7.8 and 250 µg/mL. Compound 
3e showed the lowest MFC values against S. cerevisiae and the dermatophytes M. gypseum, T. rubrum 
and T. mentagrophytes. 
2.3. In Vitro Antitumor Activity 
All compounds synthesized were sent to the U.S. National Cancer Institute (NCI) to evaluate 
antitumor activity. The results showed that only compound 3c had an interesting antitumor activity and 
therefore was evaluated against 60 different cell lines (melanoma, leukemia, lung cancer, colon, brain, 
breast, ovary, kidney and prostate). In order to determine its cytostatic activity compound 3c was 
evaluated at five concentrations (100, 10, 1.0, 0.1 and 0.001 μM). Compound 3c shows an interesting 
activity against CCRF-CEM and RPMI-8226 (leukemia) (GI50: 2.50, 2.52 μM and LC50 >100 μM) 
respectively. 
It also exhibited activity against EKVX and NCI-H522 (Non-Small Cell Lung Cancer) (GI50: 3.03, 
2.96 μM and LC50 >100 μM), the most sensitive cell line was HOP-92 (Non-Small Cell Lung Cancer) 
(GI50: 0.62 μM and LC50 >100 μM). These results although moderate, open the research on these 
compounds with the aim of finding new potential antitumor agents. The LC50 found indicates a low 
toxicity of such compounds for normal human cell lines, as required for potential anti-tumor agents 
(see Table 4). 
Table 4. In vitro testing expressed as growth inhibition of cancer cell lines for compound 3c a. 
Panel/Cell Line Compound 3c GI50 b (μM) LC50 c (μM) 
Leukemia   
CCRF-CEM 2.50 >100 
HL-60(TB) 4.83 >100 
K562 7.54 >100 
MOLT-4 14.8 >100 
RPMI-8226  2.52 >100 
SR 7.29 >100 
Non Small Cell Lung   
A549/ATCC  5.88 >100 
EKVX  3.03 >100 
HOP-62  22.7 >100 
HOP-92  0.62 >100 
NCI-H226  2.03 >100 
NCI-H23  2.68 >100 
NCI-H322M  7.63 >100 
NCI-H460  5.50 54.4 
NCI-H522 2.96 >100 
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Table 4. Cont. 
Panel/Cell Line Compound 3c GI50 b (μM) LC50 c (μM) 
Colon Cancer   
COLO 205 21.2 >100 
HCC-2998  6.05 >100 
HCT-116  5.62 70.2 
HCT-15  4.71 96.2 
HT29  12.5 >100 
KM12  6.24 63.5 
SW-620 19.6 >100 
Prostate Cancer    
PC-3  5.66 >100 
DU-145 12.6 >100 
CNS Cancer   
SF-268  17.2 >100 
SF-295  3.33 82.6 
SF-539  5.53 61.0 
SNB-19  6.14 >100 
SNB-75  17.8 >100 
U251 5.54 64.8 
Melanoma   
LOX IMVI  10.0 >100 
MALME-3M  3.84 6.11 
M14 0.405  6.75 >100 
MDA-MB-435  4.91 >100 
SK-MEL-2  4.18 70.7 
SK-MEL-28  9.22 >100 
SK-MEL-5  3.19 58.4 
UACC-257  13.2 >100 
UACC-62 3.36 5.77 
Renal Cancer   
786-0  3.92 >100 
A498  2.99 94.4 
ACHN  7.40 52.1 
CAKI-1  7.15 >100 
RXF 393  22.4 >100 
SN12C  9.93 >100 
TK-10  8.00 >100 
UO-31 4.39 >100 
Breast Cancer   
MCF7 8.31 >100 
MDA-MB231/ATCC 10.1 >100 
HS 578T 6.03 >100 
BT-549 5.20 86.5 
T-47D 4.59 >100 
MDA-MB-468 6.83 >100 
a Data obtained from NCI’s in vitro disease-oriented human tumor cell lines screen [15]; b GI50 was the drug 
concentration resulting in a 50% reduction in the net protein increase (as measured by SRB staining) 
compared to control cells during the drug incubation; Determined at five concentration levels (100, 10, 1.0, 
0.1 and 0.01 mM); c LC50 is a parameter of cytotoxicity and reflects the molar concentration needed to kill 
50% of the cells. 
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3. Experimental  
3.1. General 
Reagents and solvents used below were obtained from commercial sources. Melting points were 
measured using a Stuart SMP3 melting point device. IR spectra were obtained with a Shimadzu 
IRAffinity-1. The 1H and 13C-NMR spectra were run on a Bruker DPX 400 spectrometer operating at 
400 and 100 MHz respectively, using DMSO-d6 and CDCl3 as solvents and TMS as internal standard. 
The mass spectrum was obtained on a Shimadzu-GCMS-QP2010 spectrometer operating at 70 eV. 
Microwave experiments were carried out on a focused microwave reactor (300W CEM Discover) Thin 
layer chromatography (TLC) was performed on a 0.2-mm pre-coated plates of silica gel 60GF254 
(Merck, Darmstadt, Germany). 
3.2. Synthesis 
3.2.1. General Procedure for the Synthesis of (Z)-5-Hetarylmethylidene-2-thioxothiazolidin-4-ones 3a–d 
Two drops of piperidine (0.01 equiv.) were added to an ethanolic solution of heterocyclic aldehyde 
(1a–d, 1.1 mmol) and rhodanine (2a, 1 mmol). The mixture was refluxed for 4–6 h and the solid 
formed was isolated by vacuum filtration and washed with cold ethanol. 
(Z)-5-((3-Methyl-1-phenyl-1H-pyrazol-4-yl)methylidene)-2-thioxothiazolidin-4-one (3a). Yellow solid 
(86%), m.p. 294–295 °C; FT-IR (KBr), υ: (NH) 3134, (C=O) 1684 and (C=S) 1213 cm−1; 1H-NMR 
(DMSO-d6), δ: 2.40 (s, 3H, CH3), 7.36 (t, J = 7.44 Hz, 1H, Ar-Hp), 7.39 (s, 1H, H-6), 7.51 (dd,  
J = 7.44 and 8.52 Hz, 2H, Ar-Hm), 7.93 (d, J = 8.52 Hz, 2H, Ar-Ho), 8.50 (s, 1H, H-5’), 13.71 (s, 
1H, -NH-) ppm; 13C-NMR (DMSO-d6), δ: 12.0 (-CH3), 117.0 (C-4'), 119.4 (Co), 122.3 (C-6), 123.4 
(C-5), 127.5 (Cp), 128.0 (C-5'), 130.0 (Cm), 139.1 (Ci), 152.4 (C-3'), 169.4 (C=O), 195.5 (C=S) ppm. 
MS (EI, 70 eV) m/z (%): 301 (M+, 50), 214 (100), 213 (55), 129 (22), 109 (18), 107 (13), 104 (10), 102 
(16), 96 (12), 77 (71), 70 (19), 69 (12). Anal. Calcd. for C14H11N3OS2 (301.03): C, 55.79%; H, 3.68%; 
N, 13.94%; found: C, 56.02%; H, 3.71%; N, 13.56%. 
(Z)-5-((4-Methyl-1H-imidazol-5-yl)methylidene)-2-thioxothiazolidin-4-one (3b). Orange crystalline solid 
(91%), m.p. 307–309 °C; FT-IR (KBr), υ: (NH) 3558, (NH) 3225, (C=O) 1690 and (C=S) 1217 cm−1; 
1H-NMR (DMSO-d6), δ: 2.39 (s, 3H, CH3), 7.49 (s, 1H, H-6), 7.83 (s, 1H, H-2'), 12.61 (s, 1H, NH-1'), 
13.31 (s, 1H, NH-3) ppm; 13C-NMR (DMSO-d6), δ: 9.7 (-CH3), 120.2 (C-5), 123.5 (C-6), 132.7 (C-5' 
or C-4'), 135.4 (C-5' or C-4'), 137.6 (C-2'), 169.7 (C=O), 200.2 (C=S) ppm. MS (IE, 70 eV) m/z (%): 
225 (M+, 38), 139 (10), 138 (70), 137 (100), 69 (25), 42 (13). Anal. Calcd. for C8H7N3OS2 (225.00): C, 
46.25%; H, 3.13%; N, 18.65%; found: C, 46.09%; H, 3.10%; N, 18.98%.  
(Z)-5-((1,3-Diphenyl-1H-pyrazol-4-yl)methylidene)-2-thioxothiazolidin-4-one (3c). Yellow solid 
(86%), m.p. 315–317 °C; FT-IR (KBr), υ: (NH) 3134, (C=O) 1695 and (C=S) 1223 cm−1; 1H-NMR 
(DMSO-d6), δ: 7.42 (t, J = 7.40 Hz, 1H, Ar-Hp), 7.46 (s, 1H, H-6), 7.51–7.59 (m, 5H, Ar-Hm, m',p'), 7.66 
(d, J = 8.08 Hz, 2H, Ar-Ho'), 7.99 (d, J = 8.24 Hz, 2H, Ar-Ho), 8.63 (s, 1H, H-5') ppm; 13C-NMR 
(DMSO-d6), δ: 116.3 (C-4'), 120.0 (Co), 122.3 (C-6), 125.3 (C-5), 128.0 (Cp) 129.0 (C-5'), 129.1 (Co'), 
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129.3 (Cm'), 129.4 (Cp'), 130.0 (Cm), 139.1 (Ci'), 139.4 (Ci), 154.3 (C-3'), 169.3 (C=O), 195.4 (C=S) 
ppm. MS (IE, 70 eV) m/z (%): 363 (M+, 76), 277 (21), 276 (100), 275 (39), 243 (10), 242 (10), 215 
(17), 172 (13), 77 (65), 28 (10). Anal. Calcd. for C19H13N3OS2 (363.05): C, 62.79%; H, 3.61%; N, 
11.56%; found: C, 62.57%; H, 3.89%; N, 11.32%. 
(Z)-5-((5-Methylthiophen-2-yl)methylidene)-2-thioxo-thiazolidin-4-one (3d). Orange solid (85%), m.p. 
230–231 °C; FT-IR (KBr), υ: (NH) 3143, (C=O) 1689 and (C=S) 1199 cm−1; 1H-NMR (DMSO-d6), δ: 
2.56 (s, 3H, CH3), 7.02 (d, J = 3.71 Hz, 1H, H-4') 7.54 (d, J = 3.71 Hz, 1H, H-3'), 7.82 (s, 1H, H-6), 
13.71 (s, 1H, NH) ppm; 13C-NMR (DMSO-d6), δ: 16.1 (-CH3), 121.9 (C-5), 125.6 (C-6), 128.6 (C-3'), 
135.9 (C-5'), 136.6 (C-4'), 149.9 (C-2'), 169.5 (C=O), 195.1 (C=S) ppm. MS (IE, 70 eV) m/z (%): 241 
(M+, 34), 155 (14), 154 (100), 153 (52), 121 (21), 97 (16), 77 (18), 69 (12), 59 (13). Anal. Calcd. for 
C9H7NOS3 (240.97): C, 44.79%; H, 2.92%; N, 5.80%; found: C, 45.08%; H, 3.11%; N, 5.85%. 
(Z)-5-Ethylidene-2-thioxothiazolidin-4-one (3e). Two drops of piperidine (0.01 equiv.) were added to 
an ethanolic solution of rhodanine (2a, 1 mmol) and paraldehyde (1.1 mmol). The mixture was 
refluxed for 7 h, the solution was cooled and crushed ice was added and the solid formed was isolated 
by vacuum filtration and washed with hexane and water. Purification was carried out by column 
chromatography silica gel using a mixture of CHCl3–EtOAc (30:1) as eluent. The solvent was removed 
under reduced pressure. This compound was obtained as a yellow solid (64%), m.p. 145–147 °C; FT-IR 
(KBr), υ: (NH) 3161, (C=O) 1703 and (C=S) 1219 cm−1; 1H-NMR (CDCl3), δ: 1.98 (d, J = 7.32 Hz, 3H, 
CH3), 6.99 (q, J = 7.32 Hz, 1H, H-6) 9.75 (s, 1H, NH) ppm; 13C-NMR (CDCl3), δ: 17.4 (–CH3), 130.4 
(C-5), 134.1 (C-6), 167.2 (C=O), 193.6 (C=S) ppm. MS (IE, 70 eV) m/z (%): 159 (M+, 100), 100 (25), 
72 (66), 71 (36), 45 (7). Anal. Calcd. for C5H5NOS2 (158.98): C, 37.72%; H, 3.17%; N, 8.80%; found: 
C, 37.65%; H, 3.22%; N, 8.43%. 
3.2.2. General Procedure for the Synthesis of 2-(5Z)-(Hetarylmethylidene)-4-oxo-2-thioxothiazolidin-
3-yl) Acetic Acids 4a–d 
A mixture of heterocyclic aldehyde (1a–d, 0.4 mmol) and rhodanine-3-acetic acid (2b, 0.4 mmol) in 
DMF, was subjected to irradiation with microwaves for 5 min at 100 °C and 100 W. Then, a mixture 
of ethanol:water (1:1) was added and the solid formed was isolated by vacuum filtration and washed 
with ethanol. 
(Z)-5-((3-Methyl-1-phenyl-1H-pyrazol-4-yl)methylidene)-4-oxo-2-thioxothiazolidin-3-yl acetic acid 
(4a). Yellow solid (81%), m.p. 279–281 °C; FT-IR (KBr), υ: (–COOH) 3315, (C=O) 1715 and (C=S) 
1323 cm−1; 1H-NMR (DMSO-d6), δ: 2.43 (s, 3H, CH3), 4.73 (s, 2H, –N–CH2–COOH), 7.38 (t,  
J = 7.45 Hz, 1H, Ar-Hp), 7.52 (dd, J = 7.45 and 7.95 Hz, 2H, Ar-Hm), 7.61 (s, 1H, H-6), 7.95  
(d, J = 7.95 Hz, 2H, Ar-Ho), 8.61 (s, 1H, H-5'), 13.45 (br. s., 1H, –COOH) ppm; 13C-NMR (DMSO-d6), 
δ: 11.51 (–CH3), 45.0 (–N–CH2–COOH), 116.5 (C-4'), 119.0 (Co), 124.1 (Cp), 127.1 (C-5), 128.1  
(C-6), 129.4 (C-5'), 132.1 (Cm), 138.6 (Ci), 152.2 (C-3'),165.9 (–COOH), 167.2 (C=O), 192.6 (C=S) 
ppm. MS (IE, 70 eV) m/z (%): 359 (M+, 26), 214 (91), 129 (34), 117 (80), 72 (100). Anal. Calcd. for 
C16H13N3O3S2 (359.04): C, 53.47%; H, 3.65%; N, 11.69%; found: C, 53.77%; H, 3.89%; N, 11.77%. 
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(Z)-5-((4-Methyl-1H-imidazol-5-yl)methylidene)-4-oxo-2-thioxothiazolidin-3-yl acetic acid (4b). 
Yellow solid (53%), m.p. 254–256 °C; FT-IR (KBr), υ: (COOH) 3368, (C=O) 1718 and (C=S) 1319 cm−1; 
1H-NMR (DMSO-d6), δ: 2.42 (s, 3H, CH3), 4.68 (s, 2H, –N–CH2–COOH), 7.69 (s, 1H, H-6), 7.86  
(s, 1H, H-2'), 12.70 (s, 1H, NH), 13.71 (br. s., 1H, –COOH) ppm; 13C-NMR (DMSO-d6), δ: 9.3  
(–CH3), 44.8 (–N–CH2–COOH), 116.1 (C-5), 124.7 (C-6), 132.4 (C-5'), 135.8 (C-4'), 137.3 (C-2'), 
166.3 (–COOH), 167.6 (C=O), 197.4 (C=S) ppm. MS (IE, 70 eV) m/z (%): 283 (M+, 51), 166 (9), 139 
(13), 138 (100), 72 (13). Anal. Calcd. for C10H9N3O3S2 (283.01): C, 42.39%; H, 3.20%; N, 14.83%; 
found: C, 42.55%; H, 4.10%; N, 14.44%. 
(Z)-5-((1,3-Diphenyl-1H-pyrazol-4-yl)methylidene)-4-oxo-2-thioxothiazolidin-3-yl acetic acid (4c). 
Yellow solid (92%), m.p. 263–265 °C; FT-IR (KBr), υ: (COOH) 3320, (C=O) 1715 and (C=S) 1320 cm−1; 
1H-NMR (DMSO-d6), δ: 4.67 (s, 2H, –N–CH2–COOH), 7.42 (t, J = 8.00 Hz, 1H, Ar-Hp), 7.54–7.58 (m, 
5H, Ar-Hm, m',p'), 7.64 (d, J = 7.90 Hz, 2H, Ar-Ho'), 7.66 (s, 1H, H-6), 8.04 (d, J = 8.03 Hz, 2H, Ar-Ho), 
8.80 (s, 1H, H-5') 13.23 (br. s., 1H, –COOH) ppm; 13C-NMR (DMSO-d6), δ: 44.79 (–N–CH2–COOH), 
115.4 (C-4'), 119.4 (Co), 120.7 (C-6), 123.8 (C-5), 127.6 (Co’), 128.7 (C-5'), 128.9 (Cp), 129.1 (Cm'), 
129.5.0 (Cp'), 131.0 (Cm), 138.6 (Ci'), 139.6 (Ci), 154.0 (C-3'), 166.0 (–COOH), 167.2 (C=O), 192.6 
(C=S) ppm. MS (IE, 70 eV) m/z (%): 421 (M+, 30), 276 (100), 72 (54). Anal. Calcd. for C21H15N3O3S2 
(421.06): C, 59.84%; H, 3.59%; N, 9.97%; found: C, 60.14%; H, 3.67%; N, 10.12%. 
(5Z)-((5-Methylthiophen-2-yl)methylidene)-4-oxo-2-thioxothiazolidin-3-yl acetic acid (4d). Orange 
solid (63%), m.p. 232–234 °C; FT-IR (KBr), υ: (COOH) 3320, (C=O) 1712 and (C=S) 1321 cm−1;  
1H-NMR (DMSO-d6), δ: 2.53 (s, 3H, CH3), 4.63 (s, 2H, –N–CH2–COOH), 7.05 (d, J = 3.70 Hz, 1H, 
H-4') 7.61 (d, J = 3.70 Hz, 1H, H-3'), 8.04 (s, 1H, H-6), 13.42 (br. s., 1H, –COOH) ppm; 13C-NMR 
(DMSO-d6), δ: 16.0 (–CH3), 45.82 (–N–CH2–COOH), 122.1 (C-5), 126.8 (C-6), 128.3 (C-3'), 136.9 
(C-5'), 138.2 (C-4'), 147.1 (C-2'), 165.5 (–COOH), 167.9 (C=O), 191.8 (C=S) ppm. MS (IE, 70 eV) 
m/z (%): 299 (M+, 31), 154 (100), 121 (15), 7 (8), 45 (10). Anal. Calcd. for C11H9NO3S3 (421.06): C, 
44.13%; H, 3.03%; N, 4.68%; found: C, 44.19%; H, 3.15%; N, 4.72%. 
3.2.3. General Procedure for the Synthesis of 5-Hetarylmethylidene-2-(piperidin-1-yl)thiazol-4-ones,  
5-hetarylmethylidene-2-morpholinothiazol-4-ones and (Z)-5-Ethylidene-2-morpholinothiazol-4(5H)-
ones 5a–d, 5e and 6a–d  
A mixture of piperidine or morpholine (2 mmol) and hetarylidene rhodanine derivatives 3a–b (1 mmol) 
or ethylene derivative 3e was refluxed in THF for 7–24 h. Crushed ice was added and the solid formed 
was isolated by vacuum filtration and washed with water and hexane. 
(Z)-5-((3-Methyl-1-phenyl-1H-pyrazol-4-yl)methylidene)-2-(piperidin-1-yl)thiazol-4(5H)-one (5a). 
White solid (85%), m.p. 141–143 °C; FT-IR (KBr), υ: (C=O) 1680 and (C=N, C=C) 1615, 1575,  
1547 cm−1; 1H-NMR (CDCl3), δ: 1.79 (br. s, 6H, –CH2–CH2–CH2–), 2.47 (s, 3H, CH3), 3.60 (br. s, 2H, 
N-CH2), 4.03 (br. s, 2H, N-CH2), 7.33 (t, J = 7.48 Hz, 1H, Ar-Hp), 7.49 (dd, J = 7.48 and 8.51 Hz, 2H, 
Ar-Hm), 7.66 (s, 1H, H-6), 7.69 (d, J = 8.51 Hz, 2H, Ar-Ho), 8.01 (s, 1H, H-5') ppm; 13C-NMR 
(CDCl3), δ: 12.0 (–CH3), 24.1 (–CH2–CH2–CH2–), 49.6 (N-CH2), 50.3 (N-CH2), 118.0 (C-4'), 119.2 
(Co), 120.8 (C-6), 126.1 (C-5), 126.5 (C-5'), 126.9 (Cp), 129.5 (Cm), 139.5 (Ci), 152.0 (C-3'), 173.0  
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(C-2) 180.8 (C=O) ppm. MS (IE, 70 eV) m/z (%): 352 (M+, 20), 242 (7), 215 (15), 214 (100), 213 (29), 
129 (6), 77 (8). Anal. Calcd. for C19H20N4OS (352.14): C, 64.75%; H, 5.72%; N, 15.90%; found: C, 
64.42%; H, 5.88%; N, 15.63%. 
(Z)-5-((4-Methyl-1H-imidazol-5-yl)methylidene)-2-(piperidin-1-yl)thiazol-4(5H)-one (5b). Yellow 
solid (70%), m.p. 261–262 °C; FT-IR (KBr), υ: (NH) 3294, (C=O) 1663 and (C=N, C=C) 1609, 1557, 
1539 cm−1; 1H-NMR (CDCl3), δ: 1.74 (br. s, 6H, –CH2–CH2–CH2–), 2.42 (s, 3H, CH3), 3.62 (br. s, 2H, 
N-CH2), 3.98 (br. s, 2H, N-CH2), 7.66 (s, 1H, H-6), 7.72 (s, 1H, H-2'), 10.81 (s, 1H, NH) ppm;  
13C-NMR (CDCl3), δ: 9.7 (–CH3), 26.1 (–CH2–CH2–CH2–), 49.2 (N-CH2), 50.1 (N-CH2), 121.5 (C-6), 
124.3 (C-5), 131.4 (C-5' o C-4'), 133.0 (C-5' o C-4'), 135.5 (C-2'), 177.1 (C-2), 182.3 (C=O) ppm. MS 
(IE, 70 eV) m/z (%): 276 (M+, 48), 166 (10), 139 (12), 138 (100), 137 (25). Anal. Calcd. for 
C13H16N4OS (276.10): C, 56.50%; H, 5.84%; N, 20.27%; found: C, 56.32%; H, 5.51%; N, 20.32%. 
(Z)-5-((1,3-Diphenyl-1H-pyrazol-4-yl)methylidene)-2-(piperidin-1-yl)thiazol-4(5H)-one (5c). Yellow 
solid (95%), m.p. 262–264 °C; FT-IR (KBr), υ: (C=O) 1695 and (C=N, C=C) 1606, 1572, 1535 cm−1; 
1H-NMR (CDCl3), δ: 1.84 (br. s, 6H, –CH2–CH2–CH2–), 3.61 (br. s, 2H, N-CH2), 4.03 (br. s, 2H,  
N-CH2), δ 7.38 (t, J = 7.38 Hz, 1H, Ar-Hp), 7.43–7.55 (m, 5H, Ar-Hm, m',p'), 7.70 (d, J = 8.20 Hz, 2H, 
Ar-Ho'), 7.82 (s, 1H, H-6), 7.83 (d, J = 8.64 Hz, 2H, Ar-Ho), 8.20 (s, 1H, H-5') ppm; 13C-NMR 
(CDCl3), δ: 24.0 (–CH2–CH2–CH2–), 25.4 (–CH2–CH2–CH2–), 26.2 (–CH2–CH2–CH2–), 49.6  
(N-CH2), 50.3 (N-CH2), 117.5 (C-4'), 119.5 (Co), 121.6 (C-6), 126.8 (C-5'), 127.3 (Cp) 127.8 (C-5), 
128.7 (Cp'), 128.8 (Cm'), 128.9 (Co'), 129.6 (Cm), 131.8 (Ci'), 139.5 (Ci), 154.5 (C-3'), 173.0 (C-2), 180.5 
(C=O) ppm. MS (IE, 70 eV) m/z (%): 414 (M+, 6), 276 (17), 109 (15), 38 (37), 36 (100), 18 (10), 17 
(22), 16 (15). Anal. Calcd. for C24H22N4OS (414.15): C, 69.54%; H, 5.35%; N, 13.52%; found: C, 
69.79%; H, 5.39%; N, 14.02%. 
(Z)-5-((5-Methylthiophen-2-yl)methylidene)-2-(piperidin-1-yl)thiazol-4(5H)-one (5d). Orange solid 
(93%), m.p. 194–196 °C; FT-IR (KBr), υ: (C=O) 1662 and (C=N, C=C) 1600, 1574 cm−1; 1H-NMR 
(CDCl3), δ: 1.72 (br. s, 6H, –CH2–CH2–CH2–), 2.56 (s, 3H, CH3), 3.59 (br. s, 2H, N-CH2), 4.01 (br. s, 
2H, N-CH2), 6.82 (d, J = 3.40 Hz, 1H, H-4') 7.15 (d, J = 3.40 Hz, 1H, H-3'), 7.87 (s, 1H, H-6) ppm; 
13C-NMR (CDCl3), δ: 15.8 (–CH3), 24.1 (–CH2–CH2–CH2–), 25.4 (–CH2–CH2–CH2–), 26.2  
(–CH2–CH2–CH2–), 49.6 (N-CH2), 50.3 (N-CH2), 124.3 (C-6), 125.5 (C-5), 127.0 (C-4'), 132.5 (C-3'), 
137.3 (C-2'), 145.6 (C-5'), 173.8 (C-2), 180.9 (C=O) ppm. MS (IE, 70 eV) m/z (%): 292 (M+, 24), 155 
(12), 154 (100), 153 (23). Anal. Calcd. for C14H16N2OS2 (292.07): C, 57.50%; H, 5.52%; N, 9.58%; 
found: C, 57.62%; H, 5.68%; N, 9.71%. 
(Z)-5-Ethylidene-2-morpholinothiazol-4(5H)-one (5e). Brown solid (45%), m.p. 193–195 °C; FT-IR 
(KBr), υ: (C=O) 1699 and (C=N, C=C) 1639, 1554 cm−1; 1H-NMR (CDCl3), δ: 2.00 (d, J = 7.12 Hz, 
3H, CH3), 3.56 (br. s, 2H, N-CH2), 3.81 (br. s, 4H, –CH2–O–CH2–), 4.05 (br. s, 2H, N-CH2), 6.99 (q,  
J = 7.12 Hz, 1H, H-6) ppm; 13C-NMR (CDCl3), δ: 18.3 (–CH3), 48.3 (N-CH2), 48.7 (N-CH2), 66.2  
(–OCH2–), 66.3 (–OCH2–), 130.8 (C-6), 133.1 (C-5), 173.0 (C-2) 175.0 (C=O). ppm. MS (IE, 70 eV) 
m/z (%): 212 (M+, 100), 184 (9), 113 (27), 72 (86), 71 (23), 69 (12), 42 (11). Anal. Calcd. for 
C9H12N2O2S (212.06): C, 50.92%; H, 5.70%; N, 13.20%; found: C, 50.15%; H, 5.87%; N, 13.02%. 
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(Z)-5-((3-Methyl-1-phenyl-1H-pyrazol-4-yl)methylidene)-2-morpholinothiazol-4(5H)-one (6a). White 
solid (71%), m.p. 264–265 °C; FT-IR (KBr), υ: (C=O) 1683 and (C=N, C=C) 1616, 1559, 1502 cm−1; 
1H-NMR (CDCl3), δ: 2.47 (s, 3H, CH3), 3.66 (br. s, 2H, N-CH2), 3.85 (br. s, 4H, –CH2–O–CH2–), 4.10 
(br. s, 2H, N-CH2), 7.32 (t, J = 7.46 Hz, 1H, Ar-Hp), 7.47 (dd, J = 7.46 and 8.07 Hz, 2H, Ar-Hm), 7.68 
(s, 1H, H-6), 7.69 (d, J = 8.07 Hz, 2H, Ar-Ho), 8.01 (s, 1H, H-5') ppm; 13C-NMR (CDCl3), δ: 11.9  
(–CH3), 48.6 (N-CH2), 48.8 (N-CH2), 66.2 (–OCH2–), 66.3 (–OCH2–), 117.8 (C-4'), 119.2 (Co), 121.8 
(C-6), 125.6 (C-5), 126.1 (C-5'), 127.1 (Cp), 129.5 (Cm), 139.4 (Ci), 152.1 (C-3'), 174.0 (C-2) 180.3 
(C=O) ppm. MS (IE, 70 eV) m/z (%): 354 (M+, 34), 215 (16), 214 (100), 213 (37), 129 (12), 109 (13), 
77 (29), 18 (16). Anal. Calcd. for C18H18N4O2S (354.12): C, 61.00%; H, 5.12%; N, 15.81%; found: C, 
60.73%; H, 5.32%; N, 15.42%.  
(Z)-5-((4-Methyl-1H-imidazol-5-yl)methylidene)-2-morpholinothiazol-4(5H)-one (6b). Yellow solid 
(62%), m.p. 270–272 °C; FT-IR (KBr), υ: (NH) 3389, (C=O) 1664 and (C=N, C=C) 1605, 1540 cm−1; 
1H-NMR (CDCl3), δ: 2.44 (s, 3H, CH3), 3.68 (br. s, 2H, N-CH2), 3.81 (br. s, 4H, –CH2–O–CH2–), 4.06 
(br. s, 2H, N-CH2), 7.70 (s, 1H, H-2'), 7.71 (s, 1H, H-6), 10.23 (s, 1H, NH) ppm; 13C-NMR (CDCl3), δ: 
9.6 (–CH3), 48.2 (N-CH2), 48.5 (N-CH2), 66.3 (–OCH2–), 121.9 (C-6), 124.5 (C-5), 130.9 (C-5' o C-4'), 
133.1 (C-5' o C-4'), 135.1 (C-2'), 178.3 (C-2), 181.6 (C=O) ppm. MS (IE, 70 eV) m/z (%): 278 (M+, 
18), 138 (26), 85 (28), 73 (33), 69 (37), 60 (52), 57 (42), 55 (36), 44 (100), 43 (99). Anal. Calcd. for 
C12H14N4O2S (278.08): C, 51.78%; H, 5.07%; N, 20.13%; found: C, 52.03%; H, 5.15%; N, 20.28%.  
(Z)-5-((1,3-Diphenyl-1H-pyrazol-4-yl)methylidene)-2-morpholinothiazol-4(5H)-one (6c). White solid 
(86%), m.p. 266–268 °C; FT-IR (KBr), υ: (C=O) 1681 and (C=N, C=C) 1602, 1567, 1502 cm−1;  
1H-NMR (CDCl3), δ: 3.66 (br. s, 2H, N-CH2), 3.86 (br. s, 4H, –CH2–O–CH2–), 4.10 (br. s, 2H,  
N-CH2), 7.39 (t, J = 7.44 Hz, 1H, Ar-Hp), 7.43–7.55 (m, 5H, Ar-Hm, m',p'), 7.70 (d, J = 8.17 Hz, 2H,  
Ar-Ho'), 7.82 (d, J = 8.62 Hz, 2H, Ar-Ho), 7.85 (s, 1H, H-6), 8.19 (s, 1H, H-5') ppm; 13C-NMR 
(CDCl3), δ: 48.6 (N-CH2), 48.8 (N-CH2), 66.2 (–OCH2–), 66.3 (–OCH2), 117.3 (C-4'), 119.5 (Co), 
122.6 (C-6), 126.8 (C-5'), 126.9 (C-5), 127.4 (Cp), 128.8 (Cp'), 128.9 (Cm'), 129.0 (Co'), 129.6 (Cm), 
131.7 (Ci'), 139.4 (Ci), 154.6 (C-3'), 174.0 (C-2), 180.1 (C=O) ppm. MS (IE, 70 eV) m/z (%): 416 (M+, 
44), 277 (22), 276 (100), 275 (27), 215 (10), 77 (3). Anal. Calcd. for C23H20N4O2S (416.13): C, 
66.33%; H, 4.84%; N, 13.45%; found: C, 66.12%; H, 5.03%; N, 13.62%. 
(Z)-5-((5-Methylthiophen-2-yl)methylidene)-2-morpholinothiazol-4(5H)-one (6d). Orange solid (85%), 
m.p. 206–208 °C; FT-IR (KBr), υ: (C=O) 1673 and (C=N, C=C) 1599, 1574 cm−1; 1H-NMR (CDCl3), 
δ: 2.57 (s, 3H, CH3), 3.65 (br. s, 2H, N-CH2), 3.84 (br. s, 4H, –CH2–O–CH2–), 4.08 (br. s, 2H, N-CH2), 
6.83 (d, J = 3.60 Hz, 1H, H-4') 7.18 (d, J = 3.60 Hz, 1H, H-3'), 7.91 (s, 1H, H-6) ppm; 13C-NMR 
(CDCl3), δ: 15.9 (–CH3), 48.6 (N-CH2), 48.8 (N-CH2), 66.2 (–OCH2–), 66.4 (–OCH2–), 124.6 (C-5), 
125.2 (C-6), 127.1 (C-4'), 133.0 (C-3'), 137.0 (C-2'), 146.1 (C-5'), 174.8 (C-2), 180.5 (C=O) ppm. MS 
(IE, 70 eV) m/z (%): 294 (M+, 22), 156 (9), 155 (12), 154 (100), 153 (27), 121 (10), 97 (8). Anal. 
Calcd. for C13H14N2O2S2 (294.05): C, 53.04%; H, 4.79%; N, 9.52%; found: C, 53.21%; H, 4.93%;  
N, 9.46%. 
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3.3. Antifungal Activity 
Microorganisms and media: For the antifungal evaluation, reference strains from the American 
Type Culture Collection (ATCC, Rockville, MD, USA), and Culture Collection of Centro de 
Referencia en Micología-CEREMIC (CCC, Facultad de Ciencias Bioquímicas y Farmacéuticas, 
Suipacha 531-(2000)-Rosario, Argentina), were used: C. albicans ATCC 10231, C. tropicalis CCC 
191, S. cerevisiae ATCC 9763, C. neoformans ATCC 32264, A. flavus ATCC 9170, A. fumigatus 
ATTC 26934, A. niger ATCC 9029, M. gypseum CCC 115, T. rubrum CCC 110, T. mentagrophytes 
ATCC 9972. Strains were grown on Sabouraud-chloramphenicol agar slants at 30 °C, maintained on 
slopes of Sabouraud-dextrose agar (SDA, Oxoid, Hampshire, UK), and subcultured every 15 days to 
prevent pleomorphic transformations. Inocula were obtained according to reported procedures and 
adjusted to 1–5 ×103 colony forming units (CFU)/mL [13,14]. 
3.4. Antifungal Susceptibility Testing 
Minimum Inhibitory Concentration (MIC) of each compound was determined by using broth 
microdilution techniques following the guidelines of the CLSI for yeasts [13] and for filamentous 
fungi [14]. MIC values were determined in RPMI-1640 (Sigma, St. Louis, MO, USA) buffered to pH 
7.0 with MOPS (Sigma). Microliter trays were incubated at 35 °C for yeasts and hyalohyphomycetes 
and at 28 °C for dermatophyte strains in a moist, dark chamber; MICs were recorded at 48 h for yeasts, 
and at a time according to the control fungus growth, for the rest of fungi. The susceptibilities of the 
standard drugs ketoconazole, terbinafine, and amphotericin B (obtained from Sigma-Aldrich,  
St. Louis, MO, USA) were defined as the lowest concentration of drug which resulted in total 
inhibition of fungal growth. For the assay, compound stock solutions were two-fold diluted with  
RPMI-1640 from 250 to 0.24 μg/mL (final volume = 100 μL) and a final DMSO (Sigma) concentration 
<1%. A volume of 100 μL of inoculum suspension was added to each well with the exception of the 
sterility control where sterile water was added to the well instead. MIC was defined as the minimum 
inhibitory concentration of the compound, which resulted in total inhibition of the fungal growth. 
Minimum Fungicide Concentration (MFC), the concentration of compound that kills fungi rather than 
inhibits the fungal growth, was determined by plating by duplicate 5 µL from each clear well of MIC 
determinations, onto a 150 mm SDA plate. After 48 h at 37 °C, MFCs were determined as the lowest 
concentration of each compound showing no growth3.5. 
3.5. Antitumor Activity 
All synthesized compounds were sent to the National Cancer Institute (NCI, Bethesda, MD, USA) 
to evaluate the cytotoxic activity. The process was performed in two stages. The first, consisted in 
evaluate the compounds at a single concentration of 1.0 μM. The second stage consisted of evaluating 
the compounds against 60 different cell lines (melanoma, leukemia, lung cancer, colon, brain, breast, 
ovary, kidney and prostate). The test consisted in a protocol of 48 h of continuous drug exposure using 
sulforhodamide B (SRB) protein assay to estimate cell growth [15]. 
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4. Conclusions 
New hetaryl- and alkylidenerhodanine derivatives 3a–e, and 4a–d, 5a–d and 6a–d were prepared 
from heterocyclic aldehydes 1a–d or acetaldehyde 1e. The compounds were screened by the US 
National Cancer Institute (NCI) to assess their antitumor activity against 60 different human cancer 
cell lines. Compound 3c showed high activity against HOP-92 (Non-Small Cell Lung Cancer), which 
was the most sensitive cell line, with GI50 = 0.62 μM and LC50 > 100 μM from the in vitro assays.  
In vitro antifungal activity of these compounds was also determined against 10 fungal strains. 
Compound 3e showed high activity against yeasts and dermatophyte strains, displaying the lowest 
MIC against Saccharomyces cerevisiae (MIC = 3.9 μg/mL). It is worth to take into account that we 
have found two interesting compounds: 3e, that appears to be an antifungal candidate for future 
research, and compound 3c, that could be an interesting molecule for the design of new hetaryl-
methylidenerhodanine antitumor derivatives. Due to these significant results, we have carried out 
chemical studies seeking structures that enhance the antifungal and antitumor activities. 
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